Search

Your search keyword '"Messinger D"' showing total 335 results

Search Constraints

Start Over You searched for: Author "Messinger D" Remove constraint Author: "Messinger D"
335 results on '"Messinger D"'

Search Results

1. Computational Approaches to Understanding Interaction and Development

2. Predictive impact of rare genomic copy number variations in siblings of individuals with autism spectrum disorders.

3. Predictive impact of rare genomic copy number variations in siblings of individuals with autism spectrum disorders

4. Sex and gender differences in autism spectrum disorder: Summarizing evidence gaps and identifying emerging areas of priority

5. Early Head Growth in Infants at Risk ofAutism: A Baby Siblings Research Consortium Study

6. Interstellar Polarization in the Taurus Dark Clouds, Wavelength Dependent Position Angles and Cloud Structure Near TMC-1

8. Cocaine Exposure Is Associated with Subtle Compromises of Infants' and Mothers' Social-Emotional Behavior and Dyadic Features of Their Interaction in the Face-to-Face Still-Face Paradigm

9. Photosensitisation and green egg yolks in laying hens caused by the feeding of ensiled alfalfa leaves.

12. Therapeutic reversal of prenatal pontine ID1 signaling in DIPG

19. Mitotic chromosome alignment is required for proper nuclear envelope reassembly

21. A baseline tool for predicting response to peginterferon alfa-2a in HBeAg-positive patients with chronic hepatitis B

22. Noninferiority on overall survival of every-2-weeks vs weekly schedule of cetuximab for first-line treatment of RAS wild-type metastatic colorectal cancer

25. A baseline tool for predicting response to peginterferon alfa-2a in HBeAg-positive patients with chronic hepatitis B.

26. Cetuximab + platinum-based therapy (PBT) as a first-line treatment for patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): An observational study (ENCORE)

27. A baseline tool for predicting response to peginterferon alfa-2a in HBeAg-positive patients with chronic hepatitis B

31. Responses are durable for up to 5 years after completion of peginterferon alfa-2a treatment in hepatitis B e antigen-positive patients

34. Spectropolarimetry of the 3 micron ice feature toward the becklin-neugebauer object 1

39. The observational ENCORE study: Cetuximab + platinum-based therapy (PBT) for first-line (1L) treatment of patients with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)

40. A Predictive Model for Selecting Patients with HCV Genotype 3 Chronic Infection with a High Probability of Sustained Virological Response to Peginterferon Alfa-2 alpha/Ribavirin

42. Effectiveness of Peginterferon Alfa-2a Therapy in HBeAg-Positive and HBeAg-Negative Patients with Chronic Hepatitis B: Final Results 3 Years Post-Treatment of the Prospective, Global, Observational S-Collate Study

44. A Genotype-Specific Baseline Score to Predict Response at 48 Weeks Post-Treatment to Peginterferon Alfa-2a in Patients with HBeAg-Negative Chronic Hepatitis B

45. A Genotype-Specific Baseline Score to Predict Post-Treatment Response to Peginterferon Alfa-2a in HBeAg-Positive Patients with Hepatitis B Virus Genotype B or C Infection

46. HBeAg Seroconversion Rates after Five Years of Follow-Up in Patients Treated with Peginterferon Alfa-2a (40kd) in Neptune: Final Results of the Son of Neptune Long-Term Follow-Up Study

49. 1800 Final results for overall survival (OS), the primary endpoint of the CECOG TURANDOT prospective randomised trial evaluating bevacizumab-paclitaxel (BEV-PAC) vs BEV-capecitabine (CAP) for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC)

50. PreOS (Preeclampsia Open Study), a Multicenter, Prospective, Non-Interventional Study Evaluating the Influence of the sFlt-1/PlGF Ratio on Physician Decision-Making in Pregnant Women with Suspicion of Preeclampsia

Catalog

Books, media, physical & digital resources